Dose the first patient in the pivotal Phase 3 HOPE-3 trial
Delivered after the deadline (19 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 May 2022
- Due
- 30 Jun 2022
- Delivered
- 19 Jul 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“First patient dosed in pivotal Phase 3 HOPE-3 trial expected in Q2 2022”
What we found
Evidence strength A What the grades mean
Capricor dosed the first HOPE-3 patient on July 19, 2022, three weeks after the Q2 2022 deadline.
-
A SEC Form 8-K Filing
“On July 19, 2022, the Company announced the commencement of patient dosing in the HOPE-3 clinical trial, a Phase 3 study investigating CAP-1002 for treating Duchenne muscular dystrophy.” ✓ confirmed on the page
-
B Q2 2022 Financial Results
“The second quarter was marked by important progress... highlighted by the initiation of our pivotal Phase 3 trial, HOPE-3... Treated first patient in HOPE-3” not found on the page
-
B Capricor Therapeutics Press Release
“SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR)... today announced commencement of dosing in HOPE-3, a Phase 3 clinical trial investigating CAP-1002” not found on the page
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- First patient dose
- Where
- United States
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-CAPR-002516 · Corrections policy